Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Pacific Edge Limited ( (PFGTF) ).
Pacific Edge Limited announced that Novitas, a Medicare Administrative Contractor, plans to convene an expert panel to review coverage for tests mentioned in the 2025 update to the American Urological Association’s microhematuria guideline, including Cxbladder Triage. This move is seen as a significant step in aligning Medicare policy with the updated guidelines and underscores the importance of Pacific Edge’s research and trials in shaping medical policy, potentially impacting the company’s operations and market positioning positively.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company that specializes in the development and commercialization of bladder cancer diagnostic and prognostic tests. Based in Dunedin, New Zealand, the company offers its Cxbladder tests worldwide through its certified laboratories in New Zealand and the USA. The Cxbladder suite consists of non-invasive genomic urine tests designed for risk stratification of urothelial cancer, improving patient experience and clinical efficiency.
For detailed information about PFGTF stock, go to TipRanks’ Stock Analysis page.